KARL STORZ acquires US-headquartered company to create a surgical robotics hub and drive Perfomance-Guided Surgery™

KARL STORZ收购美国总部公司，创建外科机器人中心并推动Performance-Guided Surgery™

RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the “Merger”) with the KARL STORZ Group (“KARL STORZ”).

北卡罗来纳州三角研究园和德国图特林根，2024年8月22日（环球通讯社）--Asensus Surgical，Inc.（纽约证券交易所美国代码：ASXC）（“Asensus Surgical”或“Asensus”）是手术室创新数字解决方案的全球领导者，今天宣布与KARL STORZ Group（“KARL STORZ”）的合并（“合并”）结束。

The transaction was completed following approval by the Asensus Surgical stockholders..

该交易在Asensus外科股东批准后完成。

Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a subsidiary of KARL STORZ and its common stock has ceased trading on the NYSE American Exchange..

根据合并协议的条款，KARL STORZ的全资直接子公司KARL STORZ Endoscopy America，Inc.以每股0.35美元的现金收购了Asensus Surgical的所有流通股。收购的结果是，Asensus Surgical已成为KARL STORZ的子公司，其普通股已停止在纽约证券交易所（NYSE American Exchange）交易。

'We are thrilled to complete this merger with KARL STORZ, which marks an exciting new chapter for Asensus,” said Anthony Fernando, Asensus Surgical President and CEO. “By joining forces with a leading company in endoscopy that became a system provider for integrated MedTech, we are well-positioned to accelerate the development and delivery of our innovative robotic and digital surgical solutions.

Asensus外科总裁兼首席执行官安东尼·费尔南多（AnthonyFernando）表示：“我们很高兴与卡尔·斯托斯（KarlStorz）完成这项合并，这标志着Asensus翻开了激动人心的新篇章。”。“通过与一家内窥镜检查领域的领先公司合作，该公司已成为integrated MedTech的系统供应商，我们有能力加快我们创新的机器人和数字手术解决方案的开发和交付。

This union will benefit patients and surgeons worldwide by advancing precise, safer, and more predictable surgical outcomes.'.

该联盟将通过推进精确，安全和更可预测的手术结果，使全世界的患者和外科医生受益。”

The closing of this acquisition is a significant milestone for both companies.

此次收购的完成对两家公司来说都是一个重要的里程碑。

'Asensus' cutting-edge technology and expertise in robotic surgery complements our comprehensive portfolio of surgical solutions,” said Karl-Christian Storz, CEO of KARL STORZ. “This enhances our portfolio and market presence, strengthening our position in the growing robotic and digital surgical market, particularly with the development of the next generation LUNA™ system.

Karl Storz首席执行官Karl Christian Storz说：“Asensus在机器人手术方面的尖端技术和专业知识补充了我们全面的手术解决方案组合。”。“这增强了我们的投资组合和市场占有率，巩固了我们在不断增长的机器人和数字手术市场中的地位，特别是随着下一代LUNA™系统的开发。

We are thrilled to welcome 200-plus talented Asensus team members into our company. Together, we will revolutionize healthcare by delivering better outcomes for patients and surgical teams worldwide.'.

我们非常高兴地欢迎200多名优秀的Asensus团队成员加入我们的公司。通过共同努力，我们将为全球患者和手术团队提供更好的结果，从而彻底改变医疗保健。”

Asensus was identified for acquisition by KARL STORZ for two primary reasons: the organization’s talent and technology. As a potential partner, Asensus turned out to be a perfect fit due to its similar philosophy and vision, and its experience in bringing its first-generation Senhance robot to market.

卡尔·斯托斯（KarlStorz）确定收购阿森苏（Asensus），主要有两个原因：该组织的人才和技术。作为一个潜在的合作伙伴，Asensus凭借其相似的理念和愿景，以及将第一代Senhance机器人推向市场的经验，成为了一个完美的合作伙伴。

LUNA™ is currently under development and has not been submitted to, or cleared by, the US FDA or other global regulators, and is not available for sale in any market. Jefferies LLC served as financial advisor to Asensus Surgical, and Ballard Spahr LLP served as legal counsel to Asensus Surgical. UBS Investment Bank served as financial advisor to KARL STORZ, and Ropes & Gray LLP served as legal counsel to KARL STORZ..

LUNA™目前正在开发中，尚未提交给美国FDA或其他全球监管机构或获得其批准，也未在任何市场销售。Jefferies LLC担任Asensus Surgical的财务顾问，Ballard Spahr LLP担任Asensus Surgical的法律顾问。瑞银投资银行（UBS Investment Bank）担任卡尔·斯托斯（KARL STORZ）的财务顾问，罗普斯和格雷律师事务所（Ropes&Gray LLP）担任卡尔·斯托斯（KARL STORZ）的法律顾问。

About Asensus Surgical, Inc.

关于Asensus Surgical，Inc。

Asensus Surgical is revolutionizing surgery with the first intra-operative Augmented Intelligence technology approved for use in operating rooms around the world. Recognized as an award-winning leader in digital technology, Asensus is committed to making surgery more accessible and predictable while delivering consistently superior outcomes.

Asensus Surgical是世界上第一个被批准用于手术室的术中增强智能技术，正在彻底改变手术。Asensus被公认为数字技术领域屡获殊荣的领导者，致力于使手术更容易获得和可预测，同时提供始终如一的优异结果。

Asensus’ novel approach to digitizing laparoscopy has led to system placements globally. Led by engineers, medical professionals, and industry luminaries, Asensus is powered by human ingenuity and driven by collaboration. To learn more about the Senhance® Surgical System and the new LUNA™ System in development, visit www.asensus.com..

Asensus数字化腹腔镜检查的新方法已导致全球范围内的系统放置。Asensus由工程师、医学专业人士和行业精英领导，以人类的创造力为动力，以协作为动力。要了解有关Senhance®手术系统和正在开发的新LUNA™系统的更多信息，请访问www.asensus.com。

About KARL STORZ SE & Co. KG

关于卡尔史托斯有限公司

The medical technology company KARL STORZ was founded in 1945 in Tuttlingen, Germany, and is an international leader in the world of endoscopy. Now in its third generation, the family-owned company employs 9,400 people in more than 40 countries worldwide. The company portfolio includes 13,000 products for human and veterinary medicine.

KARL STORZ医疗技术公司成立于1945年，位于德国图特林根，是内窥镜检查领域的国际领导者。这家家族企业现已发展到第三代，在全球40多个国家拥有9400名员工。该公司的产品组合包括13000种人类和兽医产品。

KARL STORZ stands for visionary design, precision craftsmanship and clinical effectiveness. Sales in the 2023 financial year amounted to 2.17 billion euros. Production sites are located in Germany, the USA, Switzerland and Estonia. KARL STORZ Endoscopy-America is a subsidiary of KARL STORZ SE & Co. KG..

卡尔·斯托斯（KARL STORZ）代表着富有远见的设计、精密的工艺和临床效果。2023财年的销售额为21.7亿欧元。生产基地位于德国、美国、瑞士和爱沙尼亚。KARL STORZ Endoscopy America是KARL STORZ SE&Co.KG的子公司。

Caution Regarding Forward Looking Statements

关于前瞻性声明的注意事项

This communication includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include statements concerning anticipated future events and expectations that are not historical facts. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

该通信包括1995年《私人证券诉讼改革法案》所指的某些前瞻性声明。此类声明包括关于预期未来事件和非历史事实预期的声明。除历史事实陈述外的所有陈述均为可被视为前瞻性陈述的陈述。

Actual results may vary materially from those expressed or implied by the forward-looking statements herein due to risks and uncertainties. These risks and uncertainties include, but are not limited to, those associated with the future development and commercial success of Asensus’ robotic and digital surgical solutions..

由于风险和不确定性，实际结果可能与本文前瞻性声明中明示或暗示的结果有很大差异。这些风险和不确定性包括但不限于与Asensus机器人和数字手术解决方案的未来发展和商业成功相关的风险和不确定性。

KARL STORZ MEDIA CONTACT:

KARL STORZ媒体联系人：

Anja Ebert Senior Director Corporate Communications KARL STORZ SE & Co. KG                                                                                          press@karlstorz.com +49 162 2800649

Anja Ebert企业传播高级总监KARL STORZ SE&Co.KGpress@karlstorz.com+49 162 2800649

INVESTORS                                                                                                                                    Mark Klausner or Mike Vallie ICR Westwicke invest@asensus.com 443-213-0499

投资者Mark Klausner或Mike Vallie ICR Westwickeinvest@asensus.com443-213-0499

MEDIA     Dan Ventresca Matter Communications AsensusPR@matternow.com 617-874-5488

媒体Dan Ventresca Matter CommunicationsAsensusPR@matternow.com617-874-5488

Source: Asensus Surgical, Inc.

资料来源：Asensus Surgical，Inc。